Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | AR | P10275 | 13/20 | 0.48 |
| ▸ | CACNA1H | O95180 | 1/20 | 0.34 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.33 |
| ▸ | POLB | P06746 | 1/20 | 0.33 |
| ▸ | MAPT | P10636 | 1/20 | 0.33 |
| ▸ | HPGD | P15428 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1636643 | 0.84 | AR (0.56) | ARCACNA1HKDM4EPOLBMAPT | |
| SCHEMBL12724600 | 0.80 | AR (0.42) | ARCACNA1HKDM4EPOLBMAPT | |
| SCHEMBL1636632 | 0.77 | AR (0.66) | ARCACNA1HKDM4EPOLBMAPT | |
| SCHEMBL1636551 | 0.76 | AR (0.44) | ARKDM4EPOLBMAPTHPGD | |
| SCHEMBL12395252 | 0.71 | AR (0.44) | ARKDM4EPOLBMAPTHPGD | |
| SCHEMBL20096687 | 0.70 | CACNA1H (0.41) | ARCACNA1H | |
| SCHEMBL20096569 | 0.70 | CACNA1H (0.41) | ARCACNA1H | |
| SCHEMBL29935405 | 0.69 | KDM4E (0.54) | ARKDM4EPOLBMAPTHPGD | |
| SCHEMBL1635558 | 0.68 | HDAC3 (0.42) | AR | |
| Lithium Ion SCHEMBL29942256 | 0.68 | KDM4E (0.53) | ARKDM4EPOLBMAPTHPGD |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 18 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9120830-B2 | 2-substituted benzimidazoles as selective androgen receptor modulators (SARMS) | JANSSEN PHARMACEUTICA NV (BE) | 2015-09-01 | — | — | US | disclosed |
| US-9120830-B2 | 2-substituted benzimidazoles as selective androgen receptor modulators (SARMS) | JANSSEN PHARMACEUTICA NV (BE) | 2015-09-01 | — | — | US | disclosed |
| US-20140309261-A1 | NOVEL 2-SUBSTITUTED BENZIMIDAZOLES AS SELECTIVE ANDROGEN RECEPTOR MODULATORS (SARMS) | JANSSEN PHARMACEUTICA NV (BE) | 2014-10-16 | — | — | US | disclosed |
| US-20140309261-A1 | NOVEL 2-SUBSTITUTED BENZIMIDAZOLES AS SELECTIVE ANDROGEN RECEPTOR MODULATORS (SARMS) | JANSSEN PHARMACEUTICA NV (BE) | 2014-10-16 | — | — | US | disclosed |
| US-8802865-B2 | 2-substituted benzimidazoles as selective androgen receptor modulators (SARMS) | JANSSEN PHARMACEUTICA, NV (BE) | 2014-08-12 | — | — | US | disclosed |
| US-8802865-B2 | 2-substituted benzimidazoles as selective androgen receptor modulators (SARMS) | JANSSEN PHARMACEUTICA, NV (BE) | 2014-08-12 | — | — | US | disclosed |
| US-20140031317-A1 | NOVEL 2-SUBSTITUTED BENZIMIDAZOLES AS SELECTIVE ANDROGEN RECEPTOR MODULATORS (SARMS) | JANSSEN PHARMACEUTICA, NV (BE) | 2014-01-30 | — | — | US | disclosed |
| US-20140031317-A1 | NOVEL 2-SUBSTITUTED BENZIMIDAZOLES AS SELECTIVE ANDROGEN RECEPTOR MODULATORS (SARMS) | JANSSEN PHARMACEUTICA, NV (BE) | 2014-01-30 | — | — | US | disclosed |
| US-8575206-B2 | 2-substituted benzimidazoles as selective androgen receptor modulators (SARMS) | JANSSEN PHARMACEUTICA, NV (BE) | 2013-11-05 | — | — | US | disclosed |
| US-8575206-B2 | 2-substituted benzimidazoles as selective androgen receptor modulators (SARMS) | JANSSEN PHARMACEUTICA, NV (BE) | 2013-11-05 | — | — | US | disclosed |
| EP-1984343-B1 | 2-SUBSTITUTED BENZIMIDAZOLES AS SELECTIVE ANDROGEN RECEPTOR MODULATORS (SARMS) | JANSSEN PHARMACEUTICA NV (BE) | 2013-02-27 | — | — | EP | disclosed |
| EP-1984343-B1 | 2-SUBSTITUTED BENZIMIDAZOLES AS SELECTIVE ANDROGEN RECEPTOR MODULATORS (SARMS) | JANSSEN PHARMACEUTICA NV (BE) | 2013-02-27 | — | — | EP | disclosed |
| US-20110166102-A1 | NOVEL 2-SUBSTITUTED BENZIMIDAZOLES AS SELECTIVE ANDROGEN RECEPTOR MODULATORS (SARMS) | ALFORD JR VERNON C | 2011-07-07 | — | — | US | disclosed |
| US-20110166102-A1 | NOVEL 2-SUBSTITUTED BENZIMIDAZOLES AS SELECTIVE ANDROGEN RECEPTOR MODULATORS (SARMS) | ALFORD JR VERNON C | 2011-07-07 | — | — | US | disclosed |
| US-7932399-B2 | 2-substituted benzimidazoles as selective androgen receptor modulators (SARMS) | JANSSEN PHARMACEUTICA NV (BE) | 2011-04-26 | — | — | US | disclosed |
| EP-1984343-A2 | 2-SUBSTITUTED BENZIMIDAZOLES AS SELECTIVE ANDROGEN RECEPTOR MODULATORS (SARMS) | Janssen Pharmaceutica, N.V. (BE) | 2008-10-29 | — | — | EP | disclosed |
| US-20070208014-A1 | NOVEL 2-SUBSTITUTED BENZIMIDAZOLES AS SELECTIVE ANDROGEN RECEPTOR MODULATORS (SARMS) | JANSSEN PHARMACEUTICA N.V. (BE) | 2007-09-06 | — | — | US | disclosed |
| WO-2007087518-A2 | 2-SUBSTITUTED BENZIMIDAZOLES AS SELECTIVE ANDROGEN RECEPTOR MODULATORS (SARMS) | JANSSEN PHARMACEUTICA N.V. (BE) | 2007-08-02 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20140031317-A1 | NOVEL 2-SUBSTITUTED BENZIMIDAZOLES AS SELECTIVE ANDROGEN RECEPTOR MODULATORS (SARMS) | AR, NR5A1, NR5A2 | AR 1/4885CACNA1H 4193/4885KDM4E 819/4885 |
| US-20110166102-A1 | NOVEL 2-SUBSTITUTED BENZIMIDAZOLES AS SELECTIVE ANDROGEN RECEPTOR MODULATORS (SARMS) | AR, NR5A1, NR5A2 | AR 1/4885CACNA1H 4193/4885KDM4E 819/4885 |
| US-20070208014-A1 | NOVEL 2-SUBSTITUTED BENZIMIDAZOLES AS SELECTIVE ANDROGEN RECEPTOR MODULATORS (SARMS) | AR, NR5A1, NR5A2 | AR 1/4885CACNA1H 4193/4885KDM4E 819/4885 |
| US-20140309261-A1 | NOVEL 2-SUBSTITUTED BENZIMIDAZOLES AS SELECTIVE ANDROGEN RECEPTOR MODULATORS (SARMS) | AR, NR5A1, NR5A2 | AR 1/4885CACNA1H 4193/4885KDM4E 819/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.